Mahmoud Khaimi, MD
Glaucoma Specialist · Edmond, OKNPI 1881745651
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,021,325 of the $1,306,745 with a category attached, or 78.2%. Nova Eye, Inc. accounts for 70.0% of it on its own, with 17 other manufacturers making up the rest.
Across 291 payments — averaging $4490.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nova Eye, Inc.$914K
- Ellexiscience$225K
- Lumibird Medical Inc.$61K
- Iridex Corporation$61K
- Ocular Therapeutix, Inc.$30K
- Bausch & Lomb Americas Inc.$9K
- plus $6K from 12 others
Across 46 payments — averaging $4009.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$176K
- Alcon Research LLC$8K
- Glaukos Corporation$669
What the payments were for
- Consulting fees$1,021,32578%
- Speaking & faculty fees$214,32416%
- Travel & lodging$46,9984%
- Food & beverage$15,1241%
- Education$8,9741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nova Eye, Inc. | 82 | $914,421 |
| Ellexiscience | 4 | $224,832 |
| Lumibird Medical Inc. | 13 | $61,291 |
| Iridex Corporation | 20 | $60,993 |
| Ocular Therapeutix, Inc. | 46 | $30,360 |
| Bausch & Lomb Americas Inc. | 22 | $8,914 |
| Glaukos Corporation | 11 | $4,052 |
| Alcon | 28 | $700 |
| AbbVie(2 entities) | 46 | $617 |
| Sight Sciences, Inc. | 4 | $297 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $97 |
| Thea Pharma Inc. | 2 | $42 |
| Kala Pharmaceuticals, Inc. | 2 | $33 |
| Rxsight Inc | 1 | $28 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| NEW World Medical,inc. | 1 | $21 |
| Novartis | 1 | $14 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iTrack Microcatheter for Canaloplasty$60,791
- DEXTENZA$29,537
- PRESERFLO MicroShunt$3,885
- Tango SLT/YAG Combination Laser$500
- OMNI(R) SURGICAL SYSTEM (US)$266
- Hydrus Microstent$138
- Rhopressa$117
- Rocklatan$117
How this compares
Too few glaucoma specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 88 | $35,510 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 66 | $14,728 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $13,248 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 64 | $9,349 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 416 | $9,246 |
| Travoprost | 41 | $7,721 |
| Prednisolone Acetate | 124 | $7,517 |
| Brimonidine Tartrate | 257 | $7,035 |
| Alphagan PBrimonidine Tartrate | 17 | $6,568 |
| Latanoprost | 498 | $6,258 |
| Methazolamide | 12 | $5,470 |
| RhopressaNetarsudil Mesylate | 12 | $4,381 |
| Dorzolamide Hcl | 230 | $4,033 |
| Brinzolamide | 11 | $2,489 |
| Timolol Maleate | 275 | $2,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $617 | $55,326132 claims |
| AlconSimbrinza | $700 | $14,72866 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $12 | $4,38112 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $97 | $1,36911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Edmond
- Basil MathewsEdmond$7K
- Steven SarkisianOklahoma City$413K
- Ben HarveyOklahoma City$36K
- Andrew BaileyOklahoma City$3K
- Gregory SkutaOklahoma City$872
- Anthony EconomouTulsa$279
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.